Hjem › Spiserørkreft › Massachusetts › Boston
Kliniske studier for Spiserørkreft i Boston, MA
23 studier for Spiserørkreft søker deltakere på steder i og rundt Boston (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekruttererFase 1
- Massachusetts General Hospital, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RekruttererFase 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
Rekrutterer
- Dana-Farber Cancer Institute, Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RekruttererFase 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
RekruttererFase 1
- Massachusetts General Hospital, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RekruttererFase 1/2
- Tufts Medical Center, Boston
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
RekruttererFase 2
- Massachusetts General Hospital (Data Collection Only), Boston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RekruttererFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RekruttererFase 1
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekruttererFase 1/2
- Dana Farber Cancer Institute, Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RekruttererFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
RekruttererFase 3
- Massachusetts General Hospital, Boston
Resilience and Equity in Aging, Cancer, and Health (REACH)
Rekrutterer
- Dana-Farber Cancer Institute, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekruttererFase 1
- Dana Farber Cancer Institute, Boston
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
RekruttererFase 3
- Research Site, Boston
Serial MRI Scans During Radiation Therapy
Rekrutterer
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
RekruttererFase 2
- Massachusetts General Hospital, Boston
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
RekruttererFase 1
- Mass General Cancer Center, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RekruttererFase 1/2
- Massachusetts General Hospital Cancer Center, Boston
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
RekruttererFase 1/2
- Massachusetts General Hospital - Dana Farber, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RekruttererFase 1
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- og 2 flere
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RekruttererFase 1/2
- Massachusetts General Hospital, Boston
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
RekruttererFase 1/2
- Massachusetts General Hospital, Boston
Spiserørkreft-studier i andre byer
- Houston, TX36 studier
- New York City, NY22 studier
- Nashville, TN19 studier
- St. Louis, MO17 studier
- Pittsburgh, PA15 studier
- Los Angeles, CA15 studier
- Baldwin Park, CA14 studier
- Grand Rapids, MI14 studier
- Philadelphia, PA13 studier
- San Antonio, TX12 studier
- Rochester, MN11 studier
- Arlington, VA11 studier
Andre studier i Boston
- Brystkreft112 studier
- Ikke-småcellet lungekreft90 studier
- Kreft (alle typer)85 studier
- Metastatisk kreft63 studier
- Kolorektal kreft63 studier
- Lungekreft62 studier
- Eggstokkreft61 studier
- Prostatakreft59 studier
- Depresjon52 studier
- Endometriekreft50 studier
- Hjertesvikt44 studier
- Akut myelogen leukemi44 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.